Effects of Transcranial Direct Current Stimulation on Clinical Outcomes, Calcitonin Gene-Related Peptide, and Pituitary Adenylate Cyclase-Activating Polypeptide-38 Levels in Menstrual Migraine

Plain-language guide to PMID 38506767 (2024): parallel-group randomized controlled trial study of CGRP (Calcitonin Gene-Related Peptide) and PACAP in 58 patients, migraine.

Key Facts

PMID: 38506767
Journal: Neuromodulation : journal of the International Neuromodulation Society
Year: 2024
Study type: Randomized Controlled Trial
Authors: Hasırcı Bayır BR et al. (11 authors)
DOI: 10.1016/j.neurom.2024.01.005

What This Study Did, in Plain Language

What Was Tested

This randomized controlled trial paper looks at CGRP (Calcitonin Gene-Related Peptide) and PACAP in the context of migraine.

Who Took Part

The abstract describes 58 patients taking part.

The age groups tagged for this paper are teenagers, young adults, adults and middle-aged adults, women only.

In this parallel study, 58 female patients between the ages of 18 and 45 years, including 36 with MRM and 22 with nonmenstrual migraines (nMM), were recruited.

Migraine attack frequency, severity, analgesic usage, CGRP, and PACAP-38 levels of the patients were evaluated before and one month after tDCS.

How the Study Was Run

The design is described as randomized and parallel-group.

The patients were allocated by chance, so the CGRP (Calcitonin Gene-Related Peptide) group and the comparison group should start out alike.

The CGRP (Calcitonin Gene-Related Peptide) group and the comparison group ran side by side rather than switching.

Sessions of 2-mA 20-minute anodal tDCS were administered over the left dorsolateral prefrontal cortex within three consecutive days (1:1 active and sham stimulation).

What Was Measured

The subject headings attached to it are Pituitary Adenylate Cyclase-Activating Polypeptide, Migraine Disorders, Calcitonin Gene-Related Peptide and Transcranial Direct Current Stimulation.

Author keywords: menstrual migraine, migraine prophylaxis and pituitary adenylate cyclase-activating peptide 38.

What This Means in Plain Language

The paper is a randomized and parallel-group study of CGRP (Calcitonin Gene-Related Peptide) and PACAP in 58 patients in people with migraine.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2024 (Neuromodulation : journal of the International Neuromodulation Society), a journal based in United States.

More context: the CGRP (Calcitonin Gene-Related Peptide) compound page and the PACAP compound page, Migraine research.

Our Notes on the Compounds

CGRP (Calcitonin Gene-Related Peptide): A 37-amino-acid neuropeptide that widens blood vessels and is involved in migraine; given in research provocation studies.

PACAP: Pituitary adenylate cyclase-activating polypeptide, a 38-amino-acid neuropeptide studied in migraine provocation research.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.